Winter is coming for the Startup Scene: Let's overcome it by entering the Asian market!
About this event
Recent trends in the global markets has posed unique challenges for each startup, however, it is not all doom and gloom! Startups are finding new ways to navigate and remain resilient during these times, and are looking beyond the borders of their own countries and markets for expansion.
In this session, we bring together three Startup Grind chapters within Asia: Seoul, Singapore and Osaka, as we talk about how startups can navigate entering new markets within Asia and hear first hand from a panel of founders on how they navigated market entry themselves.
For this panel, we will be introducing:
>Theodoric Chew, Co-Founder & CEO of Intellect, Asia Pacific’s largest employee mental health benefits company that provides comprehensive mental healthcare for leading regional workforces and consumers. Today, Intellect serves over 3 million members worldwide, including leading employers the likes of Shopee, foodpanda, Grab, Shopback, Singtel, and many more.
>Ian Low, Founder & CEO of Trabble, a B2B guest engagement SaaS platform for travel and hospitality businesses. Intent on using data and technology to better serve travellers through conversations, he taps on his extensive experience in startup consulting and venture capital across the region, to spearhead the growth of Trabble through especially challenging times during the Covid-19 pandemic especially for the hospitality industry, expanding the company and making inroads into major East Asian markets.
>Namuun Bayasgalan, Business Development Manager at what3words, a global addressing solution company, which has divided the world into 3 meter squares and given each square a unique 3 word address. Everywhere in the world can now be found and navigated by using 3 simple words. what3words' partners include Kakao Map, Mercedes-Benz, DHL, and many emergency services across the world.
>Dr. Seungpyo Hong, President and CEO of Capio Biosciences, an innovative solution to use circulating tumor cells (CTCs) and tumor-derived exosomes as biopsy-free biomarkers. Their aim is to deliver high-value oncology diagnostics that can help inform patient care decisions and improve outcomes for cancer patients.
Register for the event now and join us online on July 27th! We look forward to seeing you there.